Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D04LAQ
|
||||
Former ID |
DIB009061
|
||||
Drug Name |
Candoxatrilat
|
||||
Synonyms |
BAN; Candoxatrilat < Rec INN; UK-69578; UK-73967; Cis-4-[[[1-[2-Carboxy-3-(2-methoxyethoxy)propyl]cyclopentyl]carbonyl]amino]cyclohexanecarboxylic acid; (+)-cis-4-[1-[(S)-2-Carboxy-3-(2-methoxyethoxy)propyl]cyclopentylcarbonylamino]cyclohexanecarboxylic acid; 3-[1-(4-cis-Carboxycyclohexylcarbamoyl)cyclopentyl]-2(R,S)-(2-methoxyethoxymethyl)propanoic acid
|
||||
Drug Type |
Small molecular drug
|
||||
Structure |
Download2D MOL |
||||
Formula |
C20H33NO7
|
||||
InChI |
InChI=1S/C20H33NO7/c1-27-10-11-28-13-15(18(24)25)12-20(8-2-3-9-20)19(26)21-16-6-4-14(5-7-16)17(22)23/h14-16H,2-13H2,1H3,(H,21,26)(H,22,23)(H,24,25)/t14-,15-,16+/m0/s1
|
||||
InChIKey |
ACZWIDANLCXHBM-HRCADAONSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Neutral endopeptidase | Target Info | Inhibitor | [526732], [531869] | |
NetPath Pathway | EGFR1 Signaling Pathway | ||||
TGF_beta_Receptor Signaling Pathway | |||||
References | |||||
Ref 541626 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6491). | ||||
Ref 544971 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001740) | ||||
Ref 526732 | Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension. J Hypertens. 1992 Mar;10(3):271-7. | ||||
Ref 531869 | The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sci. 2012 Oct 15;91(13-14):743-8. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.